Universal Health Services, Inc. — Q3 2023 Form 10-Q Summary
Business context and reporting period
UHS operates acute-care hospitals, outpatient facilities and behavioral-health facilities in the United States, United Kingdom, Puerto Rico and Washington, D.C. As of September 30, 2023, it owned or operated 358 inpatient and 43 outpatient and other facilities. The filing covers the three and nine months ended September 30, 2023; financial statements are unaudited.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Net revenues | $3.563B | $3.336B | $10.578B | $9.952B |
| Income from operations | $285M | $276M | $844M | $742M |
| Operating margin | 8.0% | 8.3% | 8.0% | 7.5% |
| Income before taxes | $221M | $234M | $659M | $644M |
| Net income attributable to UHS | $167M | $183M | $501M | $501M |
| Diluted EPS | $2.40 | $2.50 | $7.09 | $6.71 |
- Q3 revenue increased 6.8%; nine-month revenue increased 6.3%. Same-facility revenue increased 7.5% in both the acute-care and behavioral-health businesses during Q3.
- Q3 net income attributable to UHS declined 9%, primarily because higher interest expense and other unfavorable items more than offset operating improvement. Nine-month net income was essentially unchanged.
- Q3 same-facility acute-care income before taxes increased 2% to $135M, while behavioral-health income before taxes increased 10% to $265M. Nine-month same-facility income before taxes increased 8% in acute care and 13% in behavioral health.
- Net cash provided by operating activities was $815M for the first nine months, compared with $699M in the prior-year period. Capital expenditures were $537M, producing operating cash flow less capital expenditures of approximately $279M before other investing and financing activity.
- Cash and cash equivalents were $81M at September 30, 2023; cash, cash equivalents and restricted cash totaled $181M. Accounts receivable increased to $2.234B from $2.018B at December 31, 2022, and days sales outstanding increased to 58 days from 52 days at September 30, 2022.
- Total debt carrying value was approximately $4.9B, with fair value of approximately $4.5B. Debt represented approximately 45% of total capitalization. The company had $721M of available revolving-credit capacity, net of $475M of borrowings and $4M of letters of credit, and was in compliance with its debt covenants.
- Interest expense increased to $153M from $83M for the first nine months. Average borrowing cost was approximately 4.85% versus 2.53% in the comparable period, while average borrowings increased to $4.61B from $4.37B.
Material changes versus the prior comparable period
- Acute-care admissions increased 6.2% and adjusted admissions increased 6.8% in Q3; occupancy increased to 64% from 62%. Behavioral-health admissions increased 0.5%, with occupancy unchanged at 72%.
- Acute-care physician-related expenses increased $29M in Q3 and $91M for the first nine months, particularly in emergency-room care and anesthesiology.
- Behavioral-health revenue growth and improved operating leverage were key contributors to earnings growth. U.K. behavioral-health revenue increased to approximately $203M in Q3 from $167M and to $561M for the first nine months from $516M.
- Desert Springs Hospital Medical Center discontinued inpatient operations in the first quarter of 2023, reducing revenue by approximately $44M in Q3 and $121M for the first nine months compared with the prior-year periods.
- Professional and general liability reserves increased by $25M during the first nine months of 2023, while workers’ compensation reserves decreased by approximately $10M based on favorable claims trends.
- UHS repurchased $385M of common stock during the first nine months, including $367M of open-market purchases, and paid $42M of dividends. Q3 repurchases under the announced program totaled $175M.
- COVID-related revenue declined materially: Q3 2023 included no revenue from the COVID uninsured program or Medicare sequestration relief, and no Medicare COVID add-on revenue, compared with certain amounts in 2022.
Guidance, outlook, commentary and risks
- Management expects full-year 2023 capital expenditures of approximately $725M to $775M; $537M had been spent through September 30.
- Management estimates a 2023 net benefit of approximately $525M from Texas and other state Medicaid supplemental-payment programs, net of approximately $297M of provider taxes. These amounts depend on continued governmental approvals, required intergovernmental transfers and program terms.
- Management expects approximately $9M of additional Texas Quality Incentive Fund revenue in Q4 2023 and approximately $3M per quarter of HARP revenue beginning in Q4.
- Key operating pressures include clinical labor shortages, temporary labor and wage premiums, inflation, higher hospital-based physician costs, elevated interest rates and potential limits on passing costs through to government payers.
- Medicaid and Medicare reimbursement changes remain material risks. The filing highlights scheduled Medicaid DSH reductions, Medicaid eligibility redeterminations, possible changes to supplemental-payment programs and the proposed Medicaid Managed Care Rule.
- The company maintains $429M of professional and general liability accruals and $127M of workers’ compensation accruals. Future reserve adjustments could materially affect results.
- UHS is subject to healthcare regulatory investigations, False Claims Act and other litigation risks. The Pennsylvania Medicaid DSH repayment dispute and the Knight shareholder derivative litigation remain unresolved; potential exposure cannot be reliably estimated from the filing.
- UHS has committed to develop, lease and operate District Facilities in Washington, D.C. Construction is expected to be completed in 2025, with projected aggregate costs of approximately $439M funded by the District; approximately $152M had been incurred by September 30, 2023.
- Management states that operating cash flow, cash, available credit and capital-market access should provide sufficient resources for the next twelve months, but cautions that future financing may not be available on acceptable terms.
Most important facts for investors to verify
- Whether same-facility volume and revenue growth can offset physician, labor, inflationary and interest-cost pressures.
- The sustainability and renewal of Medicaid supplemental-payment programs, including Texas programs and the impact of potential DSH reductions.
- Accounts-receivable aging, collection trends and the increase in days sales outstanding.
- Debt refinancing and maturity exposure, particularly the $2.29B term loan and debt maturities concentrated around 2026.
- Future professional-liability reserve development and outcomes of the Pennsylvania DSH dispute, Knight litigation and other regulatory matters.
- Actual 2023 capital expenditures, share repurchases and resulting leverage and liquidity.